Some pediatricians introduced in its pediatric hospital medicine is used initially will be upper respiratory tract infection, then see “Clinical Drug Information Reference 2007 Edition” A lot of vidarabine drug toxicity, but also set out the United States was disabled drug injection preparations. As early as 2010 the hospital for safety reasons, we recommend caution in children, pediatric rarely used for upper respiratory tract infections.

CFDA informed that 5.05% of adverse reaction case reports of serious adverse reactions related to the database with a single injection of Ara-AMP reports the total number of reports of NDC, reports of adverse reactions children under 14 accounted for about 80%. In recent years, injection vidarabine monophosphate cases of adverse reactions showed rapid growth trend in the number of reports, and more serious adverse reaction reports. Injection adenosine monophosphate can cause severe allergic reactions, such as anaphylactic shock, anaphylactoid reactions, breathing difficulties; may also cause mental disorders, nerve damage (such as tremors, numbness of the limbs, convulsions, unconsciousness, etc.) and bone marrow suppression (such as red blood cells, leukopenia, thrombocytopenia, and so on).

Food Drug Administration recommends that medical personnel before using this product should be asked in detail about the patient’s allergies, allergy to the chemicals contained in the disabled, allergic caution. Close observation of patients during the administration once an exception should be discontinued immediately and treatment. Because there is no application for children injection vidarabine monophosphate safety and effectiveness of the system of research data, recommendations for children to be weighed. It is also recommended to strengthen the company injection vidarabine monophosphate security monitoring, particularly concerned about the safety of children medication.